ArticleACS omega2025
Aesculetin Suppresses Airway Epithelial Barrier Disruption Induced by Inhalation of Urban Coarse Particulate: Involvement of Neutrophil Elastase and Protease-Activated Receptor‑2.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Particulate matter (PM) is a mixture of solid and liquid air pollutants floating in the air, and it is the most harmful form of air pollutant because it can penetrate deep into the lungs and bloodstream and cause various breathing problems. Neutrophil elastase (NE) is known to be a major constituent of lung proteolytic activity and potently stimulates mucus secretion during airway inflammation. Aesculetin is a coumarin derivative that has anti-inflammatory properties in blood vessels and the immune system. This study investigated whether aesculetin inhibited bronchial barrier destruction caused by urban PM10 (uPM10, particles less than 10 μm). Balb/c mice were orally administrated with 10 mg/kg aesculetin while inhaling 6 μg/mL of uPM10 for 8 weeks. In addition, human bronchial epithelial BEAS-2B cells were exposed to 2 μg/mL uPM10 or 0.5 μg/mL NE in the presence of 1-20 μM aesculetin. Oral administration of aesculetin attenuated neutrophil infiltration and accumulation in the small airways inflamed by uPM10 and suppressed NE-mediated neutrophil inflammation in the airways. The supplementation of aesculetin boosted bronchial levels of junction proteins of occludin-1 and ZO-1, depleted due to uPM10 inhalation, indicating that this compound blocked airway epithelial barrier disruption caused by uPM10. Consistently, aesculetin enhanced the induction of occludin-1 and ZO-1 in BEAS-2B cells exposed to either uPM10 or NE. On the other hand, aesculetin suppressed bronchial matrix metalloproteinase (MMP)-2 in uPM10-loaded mice. Moreover, aesculetin inhibited the bronchial induction of protease-activated receptor (PAR)-2. Collectively, aesculetin improved the upper airways damaged by the inhalation of urban coarse PM through inhibiting NE-driven neutrophil inflammation and MMP-2 activation involving PAR-2. Therefore, anti-inflammatory aesculetin may be a promising natural agent to strengthen the airway epithelial barrier disrupted by activation of PAR-2-NE and PAR-2-MMP-2 in dusty urban environments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.